NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY, http://novabaypharma.com), will conduct a conference call and webcast to discuss its fourth quarter and year end 2007 results and provide a corporate update on March 11, 2008. The call will be conducted by Ron Najafi, Chief Executive Officer and Tom Paulson, Chief Financial Officer and will begin at 11:00am EST. The Company’s results for the fourth quarter and year ended December 31, 2007 will be released on March 11, 2008 prior to the webcast. Discussion during the conference call may also cover any material developments occurring after the date of this notice but before the date of the call.
Those interested in listening to management’s discussion may join the call by dialing 1-800-561-2813, for domestic participants and 617-614-3529 for international participants, at least ten minutes prior to the beginning of the call. When prompted, please enter pass code 11629446. Participants may also access a live webcast of the conference call through NovaBay’s website www.novabaypharma.com. A replay will be available for one week following the call by dialing 1-888-286-8010 for domestic participants, and 617-801-6888 for international participants. When prompted, please enter passcode 46546033. The presentation will be available and archived on the Company’s website until March 31, 2008.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative product candidates for the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocides, based upon small molecules generated by white blood cells that defend the body against invading pathogens. NovaBay believes that the Aganocide® compounds could form a platform on which to create a variety of products to address different needs in the prevention and treatment of bacterial, fungal and viral infections, including MRSA.
NovaBay has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide® compounds in the eye, ear and sinus and in contact lens solutions. In addition to its Aganocide® compounds, NovaBay is developing NVC-101, or NeutroPhase, and has entered into a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NeutroPhase in wound care applications.
NovaBay™, AgaNase™, Aganocide® and NeutroPhase™ are trademarks of NovaBay Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.
For more information visit the company’s website at www.novabaypharma.com
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay’s product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
The Investor Relations Group
Adam Holdsworth / Rachel Colgate / Erica Ruderman
Janet Vasquez / Laura Colontrelle